Skip to main content
Clinical Trials

Computer Assisted Assessment of Imaging and Biomarkers to Predict Genitourinary Mass Outcomes

ClinicalTrials.gov Identifier

ClinicalTrials.gov registration not required

Learn more
clinicaltrials.gov

About This Study

A Multicenter Phase II Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors to assess the antitumor activity of lurbinectedin (PM01183) in terms of overall response rate (ORR), in the following advanced solid tumors: small cell lung cancer (SCLC), head and neck carcinoma (H&N), neuroendocrine tumors (NETs), biliary tract carcinoma, endometrial carcinoma, BRCA 1/2-associated metastatic breast carcinoma, carcinoma of unknown primary site, germ cell tumors (GCTs), and Ewing's family of tumors (EFTs)